Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia

被引:51
作者
Mihara, K [1 ]
Kondo, T
Yasui-Furukori, N
Suzuki, A
Ishida, M
Ono, S
Kubota, T
Iga, T
Takarada, Y
de Vries, R
Kaneko, S
机构
[1] Hirosaki Univ, Dept Neuropsychiat, Sch Med, Hirosaki, Aomori 0368562, Japan
[2] Hirosaki Univ, Sch Med, Dept Clin Pharmacol, Hirosaki, Aomori 036, Japan
[3] Tokyo Univ Hosp, Dept Pharm, Tokyo 113, Japan
[4] TOYOBO Co Ltd, Fukui, Japan
[5] Janssen Res Fdn, Dept Drug Metab & Pharmacokinet, B-2340 Beerse, Belgium
关键词
risperidone; 9-hydroxyrisperidone; CYP2D6; genotype; steady-state plasma concentration; schizophrenia;
D O I
10.1097/00007691-200306000-00006
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The effects of various CYP2D6 genotypes on the steady-state plasma concentrations (Css) of risperidone and its active metabolite, 9-hydroxyrisperidone, were studied in 85 Japanese schizophrenic patients (27 men and 58 women) treated with 6 mg/d risperidone for at least 2 weeks. Plasma concentrations of risperidone and 9-hydroxyrisperidone were measured using liquid chromatography-tandem mass spectrometry. The patients had the following CYP2D6 genotypes: wild-type (wt)/wt (40 patients), CYP2D6*10 (*10)/wt (28), CYP2D6*5 (*5)/wt (8), *10/*10 (5), *5/*10 (3), and CYP2D6*4/CYP2D6*14 (1), respectively. The Css values of risperidone and 9-hydroxyrisperidone were corrected to the median body weight of 58 kg. The medians (ranges) of the Css of risperidone in the aforementioned genotype groups were 2.2 (0.37-35.7), 6.4 (2.1-26.5), 12.3 (4.7-39.5), 19.4 (13.4-26.4), 64.0 (41.6-68.8), and 91.8 nmol/L. Those values for risperidone-to-9-hydroxyrisperidone ratio were 0.03 (0.01-0.33), 0.06 (0.03-0.19), 0.14 (0.07-0.29), 0.28 (0.25-0.38), 0.48 (0.38-0.58), and 2.35, respectively. The Css of risperidone was significantly (P < 0.05 or P < 0.001) different among the four genotype groups (wt/wt, *10/wt, *5/wt, and *10/*10), except between the *5/wt and *10/*10 groups. Also, the risperidone-to-9-hydroxyrisperidone ratio significantly (P < 0.005 or P < 0.001) differed among these genotype groups. No significant differences were found in the Css of 9-hydroxyrisperidone and the active moiety (the Css of risperidone plus 9-hydroxyrisperidone) among these genotype groups. This study confirms previous findings that the CYP2D6 status affects the Css of risperidone via its strong regulation of 9-hydroxylation of risperidone. However, similar active moiety of risperidone among different genotype groups suggests that the determination of the CYP2D6 genotype has little importance for clinical situations.
引用
收藏
页码:287 / 293
页数:7
相关论文
共 28 条
[1]   Molecular genetics of CYP2D6:: Clinical relevance with focus on psychotropic drugs [J].
Bertilsson, L ;
Dahl, ML ;
Dalén, P ;
Al-Shurbaji, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (02) :111-122
[2]   A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A [J].
Bork, JA ;
Rogers, T ;
Wedlund, PJ ;
de Leon, J .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (07) :469-476
[3]   DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION [J].
BROLY, F ;
GAEDIGK, A ;
HEIM, M ;
EICHELBAUM, M ;
MORIKE, K ;
MEYER, UA .
DNA AND CELL BIOLOGY, 1991, 10 (08) :545-558
[4]   A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype [J].
Chida, M ;
Yokoi, T ;
Nemoto, N ;
Inaba, M ;
Kinoshita, M ;
Kamataki, T .
PHARMACOGENETICS, 1999, 9 (03) :287-293
[5]  
CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25
[6]   RISPERIDONE VERSUS HALOPERIDOL IN THE TREATMENT OF CHRONIC-SCHIZOPHRENIC INPATIENTS - A MULTICENTER DOUBLE-BLIND COMPARATIVE-STUDY [J].
CLAUS, A ;
BOLLEN, J ;
DECUYPER, H ;
ENEMAN, M ;
MALFROID, M ;
PEUSKENS, J ;
HEYLEN, S .
ACTA PSYCHIATRICA SCANDINAVICA, 1992, 85 (04) :295-305
[7]   Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4 [J].
Fang, J ;
Bourin, M ;
Baker, GB .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (02) :147-151
[8]   GENOTYPING OF POOR METABOLIZERS OF DEBRISOQUINE BY ALLELE-SPECIFIC PCR AMPLIFICATION [J].
HEIM, M ;
MEYER, UA .
LANCET, 1990, 336 (8714) :529-532
[9]   PHARMACOKINETICS OF THE NOVEL ANTIPSYCHOTIC AGENT RISPERIDONE AND THE PROLACTIN RESPONSE IN HEALTHY-SUBJECTS [J].
HUANG, ML ;
VANPEER, A ;
WOESTENBORGHS, R ;
DECOSTER, R ;
HEYKANTS, J ;
JANSEN, AAI ;
ZYLICZ, Z ;
VISSCHER, HW ;
JONKMAN, JHG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) :257-268
[10]  
JANSSEN PAJ, 1988, J PHARMACOL EXP THER, V244, P685